What is the appropriate dose of cabergoline to suppress lactation?

Cabergoline Dosing for Lactation Suppression

For postpartum lactation inhibition, administer cabergoline 1 mg as a single oral dose within 24-27 hours after delivery.

FDA-Approved Dosing

The FDA label explicitly states that cabergoline should NOT be used for routine lactation suppression 1. The label warns: "Use of cabergoline for the inhibition or suppression of physiologic lactation is not recommended" and "cabergoline should not be given to women postpartum who are breastfeeding or who are planning to breastfeed" 1.

Evidence-Based Dosing (When Medically Indicated)

Despite FDA recommendations against routine use, substantial clinical evidence supports specific dosing when lactation suppression is medically necessary or strongly desired:

Single-Dose Regimen (Preferred)

• 1 mg orally as a single dose within 24-27 hours postpartum demonstrates the highest efficacy 2, 3, 4
• Complete success rates: 78-100% 3, 5
• Superior to lower doses: 1 mg achieves 95% success versus 65% with 0.5 mg 6

Alternative Divided Dosing

• 0.25 mg twice daily for 2 days (total 1 mg) is an acceptable alternative per manufacturer recommendations 2
• This divided approach may reduce initial adverse effects while maintaining efficacy

Clinical Outcomes

Efficacy advantages of the 1 mg single dose:

• Time to lactation cessation: 0-1 days 3
• Significantly lower rebound lactation compared to bromocriptine (5 of 136 vs 23 of 136 patients) 4
• Reduced milk leakage at day 7: 9% versus 42% with pyridoxine 2
• Complete lactation inhibition by day 7: 78% versus 35% with pyridoxine 2

Safety Considerations

Common adverse effects (31% incidence):

• Dizziness, headache, nausea 2, 3
• All adverse effects are typically mild and self-limited 2, 5

Critical contraindications:

• Hypertensive disorders
• Cardiac valvular disease
• Hepatic disease
• Fibrotic disorders 2

Important caveat: While cabergoline demonstrates superior efficacy to alternatives like pyridoxine (vitamin B6 200 mg three times daily for 7 days), pyridoxine achieved adequate symptom control (mild symptoms) in 67% of patients with essentially no adverse effects 2. For women with contraindications to cabergoline, pyridoxine represents a reasonable alternative despite lower efficacy.

Practical Algorithm

1. Screen for contraindications (cardiac, hepatic, hypertensive, fibrotic disease)
2. If contraindications present: Consider pyridoxine 200 mg TID × 7 days instead
3. If no contraindications and lactation suppression medically indicated:
   • Administer cabergoline 1 mg PO as single dose within 24 hours postpartum
   • Alternative: 0.25 mg PO BID × 2 days
4. Monitor: Assess breast engorgement, pain, and milk leakage at days 2,7, and 14
5. Treatment failure: If inadequate response by day 7, consider additional 0.5 mg dose (though evidence limited)

The evidence strongly supports 1 mg single-dose cabergoline as the most effective regimen when lactation suppression is medically necessary, despite FDA recommendations against routine use for this indication.